ONO-1714 (Ono).
Ono Pharmaceuticals is developing ONO-1714, a selective inducible NO synthase modulator, for the potential treatment of sepsis and hypotension. By March 1999, ONO-1714 had entered phase I trials [354023]. By June 2002, a phase II trial in hypotension during dialysis was ongoing in Japan and clinical pharmacology trials were underway in the UK [446138]. In August 1999, Lehmann Brothers gave ONO-1714 a 10% probability of reaching the market with an expected launch in 2004. Sales were expected to peak at 50 million US dollars in 2012 [349228].
Whittle
Brendan J R
BJ
William Harvey Research Institute, St Bartholomew's & the Royal London, School of Medicine & Dentistry, Charterhouse Square, London, EC1M 6BQ, UK. b.j.whittle@mds.qmw.ac.uk